Related Experiment Video
Updated: May 27, 2026
11:05
Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
Published on: January 7, 2019
Curing APL through PML/RARA degradation by As2O3
Valerie Lallemand-Breitenbach1, Jun Zhu, Zhu Chen
1University Paris Diderot, Sorbonne Paris Cité, Hôpital St Louis 1, Avenue Claude Vellefaux, 75475 Paris, Cedex 10, France.
Trends in Molecular Medicine
|November 8, 2011
Summary
Acute promyelocytic leukemia (APL) treatment is revolutionized by retinoic acid (RA) and arsenic trioxide (As(2)O(3)). These therapies target the PML/RARA oncogene, leading to high cure rates through targeted degradation.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute promyelocytic leukemia (APL) is a blood cancer driven by the PML/RARA oncogene.
- Retinoic acid (RA) and arsenic trioxide (As(2)O(3)) have dramatically improved APL patient prognosis.
- Both treatments specifically target the PML/RARA oncogene, explaining their efficacy.
Purpose of the Study:
- To elucidate the molecular mechanisms of As(2)O(3)-induced PML/RARA degradation.
- To highlight the role of PML/RARA degradation in APL treatment response.
Main Methods:
- Review of recent physiopathological models and molecular studies.
- Analysis of arsenic binding, oxidation, sumoylation, and ubiquitination pathways.
Main Results:
- As(2)O(3) triggers PML/RARA degradation through a multi-step process.
- Key steps include arsenic binding, oxidation, sumoylation on PML nuclear bodies, and RNF4-mediated ubiquitination.
- This degradation pathway explains the targeted action of As(2)O(3) in APL.
Conclusions:
- The molecular mechanisms of As(2)O(3)-induced PML/RARA degradation are clarified.
- Targeted degradation of PML/RARA is central to the therapeutic success of As(2)O(3) and RA in APL.
- Understanding these mechanisms may lead to further advancements in APL treatment.
